UChicago Medicine Comprehensive Cancer Center
Immune-related Adverse Events (IrAEs) are unintended side effects of cancer immunotherapies. This is a new field of study and treatment, which is also referred to as immunotherapy toxicity.

The University of Chicago Medicine is spearheading research in this burgeoning field and providing patients with care and resources unequaled in the region. In fact, UChicago Medicine has the only outpatient IrAE clinical consortium in Illinois and one of few in the entire country.

Our clinical consortium, which is made up of expert physicians from nine specialties, is dedicated to IrAEs from checkpoint inhibitor-based immunotherapy for solid organ cancers, such as breast cancer, lung cancer, melanoma and many others.

The information below will give you answers to frequently asked questions about IrAEs and connect you with members of the UChicago Medicine IrAE Clinical Consortium (ICC).

Learn more about the immune-related adverse events and the ICC